Unknown

Dataset Information

0

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.


ABSTRACT: Modified vaccinia virus Ankara (MVA) is a safe, attenuated orthopoxvirus that is being developed as a vaccine vector but has demonstrated limited immunogenicity in several early-phase clinical trials. Our objective was to rationally improve the immunogenicity of MVA-based HIV/AIDS vaccines via the targeted deletion of specific poxvirus immune-modulatory genes. Vaccines expressing codon-optimized HIV subtype C consensus Env and Gag antigens were generated from MVA vector backbones that (i) harbor simultaneous deletions of four viral immune-modulatory genes, encoding an interleukin-18 (IL-18) binding protein, an IL-1? receptor, a dominant negative Toll/IL-1 signaling adapter, and CC-chemokine binding protein (MVA?4-HIV); (ii) harbor a deletion of an additional (fifth) viral gene, encoding uracil-DNA glycosylase (MVA?5-HIV); or (iii) represent the parental MVA backbone as a control (MVA-HIV). We performed head-to-head comparisons of the cellular and humoral immune responses that were elicited by these vectors during homologous prime-boost immunization regimens utilizing either high-dose (2 × 10(8) PFU) or low-dose (1 × 10(7) PFU) intramuscular immunization of rhesus macaques. At all time points, a majority of the HIV-specific T cell responses, elicited by all vectors, were directed against Env, rather than Gag, determinants, as previously observed with other vector systems. Both modified vectors elicited up to 6-fold-higher frequencies of HIV-specific CD8 and CD4 T cell responses and up to 25-fold-higher titers of Env (gp120)-specific binding (nonneutralizing) antibody responses that were relatively transient in nature. While the correlates of protection against HIV infection remain incompletely defined, our results indicate that the rational deletion of specific genes from MVA vectors can positively alter their cellular and humoral immunogenicity profiles in nonhuman primates.

SUBMITTER: Garber DA 

PROVIDER: S-EPMC3497691 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

Garber David A DA   O'Mara Leigh A LA   Gangadhara Sailaja S   McQuoid Monica M   Zhang Xiugen X   Zheng Rui R   Gill Kiran K   Verma Meena M   Yu Tianwei T   Johnson Brent B   Li Bing B   Derdeyn Cynthia A CA   Ibegbu Chris C   Altman John D JD   Hunter Eric E   Feinberg Mark B MB  

Journal of virology 20120912 23


Modified vaccinia virus Ankara (MVA) is a safe, attenuated orthopoxvirus that is being developed as a vaccine vector but has demonstrated limited immunogenicity in several early-phase clinical trials. Our objective was to rationally improve the immunogenicity of MVA-based HIV/AIDS vaccines via the targeted deletion of specific poxvirus immune-modulatory genes. Vaccines expressing codon-optimized HIV subtype C consensus Env and Gag antigens were generated from MVA vector backbones that (i) harbor  ...[more]

Similar Datasets

| S-EPMC2897629 | biostudies-literature
| S-EPMC9491075 | biostudies-literature
| S-EPMC5542451 | biostudies-literature
| S-EPMC2900180 | biostudies-literature
| S-EPMC5899102 | biostudies-literature
| S-EPMC1892755 | biostudies-literature
| S-EPMC2876636 | biostudies-literature
| S-EPMC9990026 | biostudies-literature
| S-EPMC5612284 | biostudies-literature
| S-EPMC10873322 | biostudies-literature